NRAS Mutation Results Explained

Q61 hotspots, melanoma, colorectal and MEK relevance

What each line of the report means

Specimen: Tumor tissue or blood, as stated
NRAS is a RAS-family oncogene usually found mutated at codons 12, 13 or 61.
Biomarker / finding: Q61R
The exact codon matters: Q61 changes dominate in melanoma, while codon 12/13 changes appear more often in colorectal and blood cancers.
Classification: Pathogenic, Tier I/II
NRAS mutations are well-established drivers; clinical actionability depends heavily on cancer type.
Clinical interpretation: Cancer-specific review required
The same mutation means different things in melanoma, colorectal cancer and thyroid cancer.

How this result is interpreted

  • In melanoma, NRAS mutations (about 15-20% of cases) rule out BRAF-targeted pills and point toward immunotherapy-first strategies, with MEK inhibitors considered in select settings.
  • In colorectal cancer, any RAS mutation (KRAS or NRAS) generally means anti-EGFR antibodies like cetuximab and panitumumab are unlikely to help.
  • NRAS has no widely approved direct inhibitor; its practical value today is steering treatment away from ineffective options and toward trials.

What this result cannot tell you

  • A negative NRAS result applies only to the codons and assay covered; panel reports list exactly which regions were tested.
  • The mutation's meaning is cancer-type-specific - a finding that changes therapy in one cancer may be informational only in another.
  • Low variant allele frequency can reflect low tumor content rather than a minor subclone; the report's tumor purity matters.

Questions to ask your oncologist

  • What is the exact NRAS change - which codon and which amino-acid substitution?
  • How does this result change which drugs are likely or unlikely to work for my cancer type?
  • Should BRAF and KRAS results be reviewed alongside this one before deciding on therapy?
  • Are there RAS-pathway trials relevant to my situation?

Frequently asked questions

Is there a drug that targets NRAS directly?

Not yet in routine practice. NRAS results mainly redirect treatment - away from BRAF or anti-EGFR drugs that will not work, and toward immunotherapy or RAS-pathway clinical trials.

Can a negative NRAS result be wrong?

A valid negative can still miss the alteration when tumor content is low or the assay did not cover the relevant codon. The specimen and methods sections matter.

Can someone independently review this result?

Yes. A Clarity Report can assess the exact variant, cancer type, co-alterations and current trial relevance, then return findings in writing.

Sources

Free 15-minute consultation